{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T01:25:25Z","timestamp":1784251525767,"version":"3.55.0"},"reference-count":51,"publisher":"Bentham Science Publishers Ltd.","issue":"10","funder":[{"name":"Suqian Science and Technology Plan Project, China","award":["K202014"],"award-info":[{"award-number":["K202014"]}]},{"name":"Suqian Science and Technology Plan Project, China","award":["S202006"],"award-info":[{"award-number":["S202006"]}]},{"name":"Suqian Science and Technology Plan Project, China","award":["K201907"],"award-info":[{"award-number":["K201907"]}]},{"name":"Suqian Science and Technology Plan Project, China","award":["K201906"],"award-info":[{"award-number":["K201906"]}]},{"name":"Jiangsu Key Laboratory of High-Tech Research and Development of Veterinary Biopharmaceuticals, China","award":["NSFKF201904"],"award-info":[{"award-number":["NSFKF201904"]}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMM"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec><jats:title>Abstract:<\/jats:title><jats:p>The CD99 antigen is a transmembrane protein expressed in a broad variety of tissues, particularly in hematopoietic cells, thymus, endothelial cells, etc. It participates in several crucial biological processes, including cell adhesion, migration, death, differentiation, and inflammation. CD99 has shown oncogenic or tumor suppressor roles in different types of cancer. Therefore, it has been used as a biomarker and therapeutic target for several types of cancer. Moreover, it has also been reported to be involved in several critical immune processes, such as T cell activation and differentiation, dendritic cell differentiation, and so on. Hence, CD99 may have potential values in cancer immunotherapy. Anti-CD99 antibodies have shown therapeutic effects on certain types of cancer, especially on Ewing sarcoma and T cell acute lymphoblastic leukemia (ALL). This review summarizes the recent progress of CD99 in cancer research and targeting therapies, especially in cancer immunotherapy, which may help researchers understand the crucial roles of CD99 in cancer development and design new therapeutic strategies.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1566524023666221007143513","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T04:57:01Z","timestamp":1665377821000},"page":"1028-1036","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Cell Adhesion Molecule CD99 in Cancer Immunotherapy"],"prefix":"10.2174","volume":"23","author":[{"given":"Feng","family":"Yu","sequence":"first","affiliation":[{"name":"School of Life Sciences, Jiangsu University, Zhenjiang 212013, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guodong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Affiliated Suqian First People\u2019s Hospital of Nanjing Medical University, Suqian 223812, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Affiliated Suqian First People\u2019s Hospital of Nanjing Medical University, Suqian 223812, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Affiliated Suqian First People\u2019s Hospital of Nanjing Medical University, Suqian 223812, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Wu","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory of High-Tech Research and Development of Veterinary Biopharmaceuticals, Jiangsu Agri-Animal Husbandry Vocational College, Taizhou 22530, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinggang","family":"Xu","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Jiangsu University, Zhenjiang 212013, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wu","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Jiangsu University, Zhenjiang 212013, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1910-1234","authenticated-orcid":true,"given":"Dongfeng","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Jiangsu University, Zhenjiang 212013, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3390\/genes9030159","volume":"9","author":"Manara M.","year":"2018","unstructured":"Manara M.; Pasello M.; Scotlandi K.; CD99: A cell surface protein with an oncojanus role in tumors. Genes 2018,9(3),159","journal-title":"Genes"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s12079-017-0445-z","volume":"12","author":"Pasello M.","year":"2018","unstructured":"Pasello M.; Manara M.C.; Scotlandi K.; CD99 at the crossroads of physiology and pathology. J Cell Commun Signal 2018,12(1),55-68","journal-title":"J Cell Commun Signal"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMra2028910","volume":"384","author":"Riggi N.","year":"2021","unstructured":"Riggi N.; Suv\u00e0 M.L.; Stamenkovic I.; Ewing\u2019s sarcoma. N Engl J Med 2021,384(2),154-164","journal-title":"N Engl J Med"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ejca.2005.09.015","volume":"42","author":"Scotlandi K.","year":"2006","unstructured":"Scotlandi K.; Perdichizzi S.; Bernard G.; Targeting CD99 in association with doxorubicin: An effective combined treatment for Ewing\u2019s sarcoma. Eur J Cancer 2006,42(1),91-96","journal-title":"Eur J Cancer"},{"key":"ref=5","first-page":"5134","volume":"60","author":"Scotlandi K.","year":"2000","unstructured":"Scotlandi K.; Baldini N.; Cerisano V.; CD99 engagement: an effective therapeutic strategy for Ewing tumors. Cancer Res 2000,60(18),5134-5142","journal-title":"Cancer Res"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1177\/1947601912473603","volume":"3","author":"Seol H.J.","year":"2012","unstructured":"Seol H.J.; Chang J.H.; Yamamoto J.; Overexpression of CD99 increases the migration and invasiveness of human malig-nant glioma cells. Genes Cancer 2012,3(9-10),535-549","journal-title":"Genes Cancer"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.3390\/ijms20051137","volume":"20","author":"Cardoso L.","year":"2019","unstructured":"Cardoso L.; Soares R.; Laurentino T.; Lerario A.; Marie S.; Oba-Shinjo S.; CD99 Expression in glioblastoma molecular subtypes and role in migration and invasion. Int J Mol Sci 2019,20(5),1137","journal-title":"Int J Mol Sci"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/sj.leu.2403303","volume":"18","author":"Dworzak M.N.","year":"2004","unstructured":"Dworzak M.N.; Fr\u00f6schl G.; Printz D.; CD99 expression in T-lineage ALL: implications for flow cytometric detection of mini-mal residual disease. Leukemia 2004,18(4),703-708","journal-title":"Leukemia"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"e0165210","DOI":"10.1371\/journal.pone.0165210","volume":"11","author":"Cox C.V.","year":"2016","unstructured":"Cox C.V.; Diamanti P.; Moppett J.P.; Blair A.; Investigating CD99 expression in leukemia propagating cells in childhood T cell acute lymphoblastic leukemia. PLoS One 2016,11(10),e0165210","journal-title":"PLoS One"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3233\/CBM-160608","volume":"17","author":"Enein A.A.A.","year":"2016","unstructured":"Enein A.A.A.; Rahman H.A.A.; Sharkawy N.E.; Significance of CD99 expression in T-lineage acute lymphoblastic leukemia. Cancer Biomark 2016,17(2),117-123","journal-title":"Cancer Biomark"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/bjh.15683","volume":"184","author":"Chen D.","year":"2019","unstructured":"Chen D.; Camponeschi A.; Wu Q.; CD99 expression is strongly associated with clinical outcome in children with B-cell precursor acute lymphoblastic leukaemia. Br J Haematol 2019,184(3),418-423","journal-title":"Br J Haematol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"eaaj2025","DOI":"10.1126\/scitranslmed.aaj2025","volume":"9","author":"Chung S.S.","year":"2017","unstructured":"Chung S.S.; Eng W.S.; Hu W.; CD99 is a therapeutic target on disease stem cells in myeloid malignancies. Sci Transl Med 2017,9(374),eaaj2025","journal-title":"Sci Transl Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1182\/blood.V95.1.294","volume":"95","author":"Kim S.H.","year":"2000","unstructured":"Kim S.H.; Shin Y.K.; Lee I.; Viral latent membrane protein 1 (LMP-1)\u2013induced CD99 down-regulation in B cells leads to the generation of cells with Hodgkin\u2019s and Reed-Sternberg phenotype. Blood 2000,95(1),294-300","journal-title":"Blood"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/s41379-018-0011-0","volume":"31","author":"Gao Q.","year":"2018","unstructured":"Gao Q.; Yellapantula V.; Fenelus M.; Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B-cell lymphomas with plasmacytic differentiation from primary plasma cell neoplasms. Mod Pathol 2018,31(6),881-889","journal-title":"Mod Pathol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1177\/002215540405200504","volume":"52","author":"Choi Y.L.","year":"2004","unstructured":"Choi Y.L.; Xuan Y.H.; Shin Y.K.; An immunohistochemical study of the expression of adhesion molecules in gallbladder le-sions. J Histochem Cytochem 2004,52(5),591-601","journal-title":"J Histochem Cytochem"},{"key":"ref=16","first-page":"5988","volume":"9","author":"Maitra A.","year":"2003","unstructured":"Maitra A.; Hansel D.E.; Argani P.; Global expression analysis of well-differentiated pancreatic endocrine neoplasms using oligonucleotide microarrays. Clin Cancer Res 2003,9(16 Pt 1),5988-5995","journal-title":"Clin Cancer Res"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3346\/jkms.2002.17.4.483","volume":"17","author":"Jung K.C.","year":"2002","unstructured":"Jung K.C.; Park W.S.; Bae Y.M.; Immunoreactivity of CD99 in stomach cancer. J Korean Med Sci 2002,17(4),483-489","journal-title":"J Korean Med Sci"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1091\/mbc.e05-10-0971","volume":"17","author":"Manara M.C.","year":"2006","unstructured":"Manara M.C.; Bernard G.; Lollini P.L.; CD99 acts as an oncosuppressor in osteosarcoma. Mol Biol Cell 2006,17(4),1910-1921","journal-title":"Mol Biol Cell"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"749","DOI":"10.4049\/jimmunol.161.2.749","volume":"161","author":"Choi E.Y.","year":"1998","unstructured":"Choi E.Y.; Park W.S.; Jung K.C.; Engagement of CD99 induces up-regulation of TCR and MHC class I and II molecules on the surface of human thymocytes. J Immunol 1998,161(2),749-754","journal-title":"J Immunol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0014-5793(03)00567-2","volume":"546","author":"Kim M.K.","year":"2003","unstructured":"Kim M.K.; Choi Y.L.; Kim M.K.; MHC class II engagement inhibits CD99-induced apoptosis and up-regulation of T cell recep-tor and MHC molecules in human thymocytes and T cell line. FEBS Lett 2003,546(2-3),379-384","journal-title":"FEBS Lett"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S1016-8478(23)13100-1","volume":"18","author":"Yoon S.S.","year":"2004","unstructured":"Yoon S.S.; Kim H.J.; Chung D.H.; Kim T.J.; CD99 costimulation up-regulates T cell receptor-mediated activation of JNK and AP-1. Mol Cells 2004,18(2),186-191","journal-title":"Mol Cells"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1002\/eji.201546143","volume":"46","author":"Mahiddine K.","year":"2016","unstructured":"Mahiddine K.; Mallavialle A.; Bziouech H.; Larbret F.; Bernard A.; Bernard G.; CD99 isoforms regulate CD1a expression in human monocyte-derived DCs through ATF-2\/CREB-1 phosphorylation. Eur J Immunol 2016,46(6),1460-1471","journal-title":"Eur J Immunol"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.4049\/jimmunol.159.5.2250","volume":"159","author":"Hahn J.H.","year":"1997","unstructured":"Hahn J.H.; Kim M.K.; Choi E.Y.; CD99 (MIC2) regulates the LFA-1\/ICAM-1-mediated adhesion of lymphocytes, and its gene encodes both positive and negative regulators of cellular adhesion. J Immunol 1997,159(5),2250-2258","journal-title":"J Immunol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/0161-5890(89)90100-4","volume":"26","author":"Banting G.S.","year":"1989","unstructured":"Banting G.S.; Pym B.; Darling S.M.; Goodfellow P.N.; The MIC2 gene product: Epitope mapping and structural prediction analysis define an integral membrane protein. Mol Immunol 1989,26(2),181-188","journal-title":"Mol Immunol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/ng0494-394","volume":"6","author":"Ellis N.A.","year":"1994","unstructured":"Ellis N.A.; Ye T.Z.; Patton S.; German J.; Goodfellow P.N.; Weller P.; Cloning of PBDX, an MIC2-related gene that spans the pseudo-autosomal boundary on chromosome Xp. Nat Genet 1994,6(4),394-400","journal-title":"Nat Genet"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1182\/blood.V95.5.1819.005k05_1819_1826","volume":"95","author":"Fouchet C.","year":"2000","unstructured":"Fouchet C.; Gane P.; Huet M.; A study of the coregulation and tissue specificity of XGand MIC2 gene expression in eukary-otic cells. Blood 2000,95(5),1819-1826","journal-title":"Blood"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1172\/JCI36667","volume":"120","author":"Rocchi A.","year":"2010","unstructured":"Rocchi A.; Manara M.C.; Sciandra M.; CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby con-tributes to oncogenesis. J Clin Invest 2010,120(3),668-680","journal-title":"J Clin Invest"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"e0217393","DOI":"10.1371\/journal.pone.0217393","volume":"14","author":"Takheaw N.","year":"2019","unstructured":"Takheaw N.; Earwong P.; Laopajon W.; Pata S.; Kasinrerk W.; Interaction of CD99 and its ligand upregulates IL-6 and TNF-\u03b1 upon T cell activation. PLoS One 2019,14(5),e0217393","journal-title":"PLoS One"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1186\/s13104-020-05347-0","volume":"13","author":"Takheaw N.","year":"2020","unstructured":"Takheaw N.; Pata S.; Laopajon W.; Roytrakul S.; Kasinrerk W.; The presence of membrane bound CD99 ligands on leukocyte surface. BMC Res Notes 2020,13(1),496","journal-title":"BMC Res Notes"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1182\/blood-2016-08-733394","volume":"129","author":"Goswami D.","year":"2017","unstructured":"Goswami D.; M\u00e4rz S.; Li Y.T.; Endothelial CD99 supports arrest of mouse neutrophils in venules and binds to neutrophil PILRs. Blood 2017,129(13),1811-1822","journal-title":"Blood"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"3944","DOI":"10.1038\/onc.2015.463","volume":"35","author":"Ventura S.","year":"2016","unstructured":"Ventura S.; Aryee D.N.T.; Felicetti F.; CD99 regulates neural differentiation of Ewing sarcoma cells through miR-34a-Notch-mediated control of NF-\u03baB signaling. Oncogene 2016,35(30),3944-3954","journal-title":"Oncogene"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1128\/MCB.00740-07","volume":"28","author":"Miyagawa Y.","year":"2008","unstructured":"Miyagawa Y.; Okita H.; Nakaijima H.; Inducible expression of chimeric EWS\/ETS proteins confers Ewing\u2019s family tumor-like phenotypes to human mesenchymal progenitor cells. Mol Cell Biol 2008,28(7),2125-2137","journal-title":"Mol Cell Biol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1158\/0008-5472.CAN-07-1761","volume":"68","author":"Riggi N.","year":"2008","unstructured":"Riggi N.; Suv\u00e0 M.L.; Suv\u00e0 D.; EWS-FLI-1 expression triggers a Ewing\u2019s sarcoma initiation program in primary human mes-enchymal stem cells. Cancer Res 2008,68(7),2176-2185","journal-title":"Cancer Res"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.1038\/onc.2012.403","volume":"32","author":"Franzetti G.A.","year":"2013","unstructured":"Franzetti G.A.; Laud-Duval K.; Bellanger D.; Stern M.H.; Sastre-Garau X.; Delattre O.; MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor. Oncogene 2013,32(33),3915-3921","journal-title":"Oncogene"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/14728222.2018.1464140","volume":"22","author":"Tavakkoli M.","year":"2018","unstructured":"Tavakkoli M.; Chung S.S.; Park C.Y.; Do preclinical studies suggest that CD99 is a potential therapeutic target in acute myeloid leukemia and the myelodysplastic syndromes? Expert Opin Ther Targets 2018,22(5),381-383","journal-title":"Expert Opin Ther Targets"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"6604","DOI":"10.1038\/sj.onc.1210481","volume":"26","author":"Scotlandi K.","year":"2007","unstructured":"Scotlandi K.; Zuntini M.; Manara M.C.; CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity. Oncogene 2007,26(46),6604-6618","journal-title":"Oncogene"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1158\/1078-0432.CCR-06-1785","volume":"13","author":"Lee J.H.","year":"2007","unstructured":"Lee J.H.; Kim S.H.; Wang L.H.; Clinical significance of CD99 down-regulation in gastric adenocarcinoma. Clin Cancer Res 2007,13(9),2584-2591","journal-title":"Clin Cancer Res"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"209","DOI":"10.4132\/KoreanJPathol.2014.48.3.209","volume":"48","author":"Shin S.J.","year":"2014","unstructured":"Shin S.J.; Lee H.; Jung G.; Expression of CD99 in Multiple Myeloma: A Clinicopathologic and Immunohistochemical Study of 170 Cases. Korean J Pathol 2014,48(3),209-216","journal-title":"Korean J Pathol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1002\/ijc.27518","volume":"131","author":"Edlund K.","year":"2012","unstructured":"Edlund K.; Lindskog C.; Saito A.; CD99 is a novel prognostic stromal marker in non-small cell lung cancer. Int J Cancer 2012,131(10),2264-2273","journal-title":"Int J Cancer"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000322551","volume":"125","author":"Lee S.P.","year":"2011","unstructured":"Lee S.P.; Park S.; Park J.; Hong J.; Ko Y.H.; Clinicopathologic characteristics of CD99-positive diffuse large B-cell lymphoma. Acta Haematol 2011,125(3),167-174","journal-title":"Acta Haematol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"6267","DOI":"10.1182\/blood-2010-12-324004","volume":"117","author":"Coustan-Smith E.","year":"2011","unstructured":"Coustan-Smith E.; Song G.; Clark C.; New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2011,117(23),6267-6276","journal-title":"Blood"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s00262-020-02789-0","volume":"70","author":"Takheaw N.","year":"2021","unstructured":"Takheaw N.; Sittithumcharee G.; Kariya R.; Kasinrerk W.; Okada S.; Anti-human CD99 antibody exerts potent antitumor effects in mantle cell lymphoma. Cancer Immunol Immunother 2021,70(6),1557-1567","journal-title":"Cancer Immunol Immunother"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"999","DOI":"10.3324\/haematol.2018.207001","volume":"105","author":"Vaikari V.P.","year":"2020","unstructured":"Vaikari V.P.; Du Y.; Wu S.; Clinical and preclinical characterization of CD99 isoforms in acute myeloid leukemia. Haematologica 2020,105(4),999-1012","journal-title":"Haematologica"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"102236","DOI":"10.1016\/j.nano.2020.102236","volume":"29","author":"Vaikari V.P.","year":"2020","unstructured":"Vaikari V.P.; Park M.; Keossayan L.; MacKay J.A.; Alachkar H.; Anti-CD99 scFv-ELP nanoworms for the treatment of acute myeloid leukemia. Nanomedicine 2020,29,102236","journal-title":"Nanomedicine"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1006\/cimm.1999.1470","volume":"193","author":"Wingett D.","year":"1999","unstructured":"Wingett D.; Forcier K.; Nielson C.P.; A role for CD99 in T cell activation. Cell Immunol 1999,193(1),17-23","journal-title":"Cell Immunol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cellimm.2018.10.012","volume":"335","author":"Laopajon W.","year":"2019","unstructured":"Laopajon W.; Pata S.; Takheaw N.; Surinkaew S.; Khummuang S.; Kasinrerk W.; Triggering of CD99 on monocytes by a specific monoclonal antibody regulates T cell activation. Cell Immunol 2019,335,51-58","journal-title":"Cell Immunol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"787","DOI":"10.4049\/jimmunol.166.2.787","volume":"166","author":"Sohn H.W.","year":"2001","unstructured":"Sohn H.W.; Shin Y.K.; Lee I.S.; CD99 regulates the transport of MHC class I molecules from the Golgi complex to the cell surface. J Immunol 2001,166(2),787-794","journal-title":"J Immunol"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.4049\/jimmunol.158.6.2543","volume":"158","author":"Bernard G.","year":"1997","unstructured":"Bernard G.; Breittmayer J.P.; de Matteis M.; Apoptosis of immature thymocytes mediated by E2\/CD99. J Immunol 1997,158(6),2543-2550","journal-title":"J Immunol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"4931","DOI":"10.4049\/jimmunol.166.8.4931","volume":"166","author":"Pettersen R.D.","year":"2001","unstructured":"Pettersen R.D.; Bernard G.; Olafsen M.K.; Pourtein M.; Lie S.O.; CD99 signals caspase-independent T cell death. J Immunol 2001,166(8),4931-4942","journal-title":"J Immunol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coi.2015.01.002","volume":"33","author":"Jensen M.C.","year":"2015","unstructured":"Jensen M.C.; Riddell S.R.; Designing chimeric antigen receptors to effectively and safely target tumors. Curr Opin Immunol 2015,33,9-15","journal-title":"Curr Opin Immunol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13045-021-01178-z","volume":"14","author":"Shi J.","year":"2021","unstructured":"Shi J.; Zhang Z.; Cen H.; CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity. J Hematol Oncol 2021,14(1),162","journal-title":"J Hematol Oncol"}],"container-title":["Current Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1566524023666221007143513","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/209743\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1566524023666221007143513","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T12:57:52Z","timestamp":1728133072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/209743\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1566524023666221007143513","relation":{},"ISSN":["1566-5240"],"issn-type":[{"value":"1566-5240","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-31","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}